Feasibility of Outpatient Induction Chemotherapy for Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
I. Assess the feasibility of outpatient induction therapy for acute myeloid leukemia (AML)
or advanced myelodysplastic syndrome (MDS) by examining whether > 50% of patients treated as
outpatients can complete chemotherapy without being admitted to hospital or < 5% of patients
die within 14 days of beginning outpatient chemotherapy.
Patients receive outpatient induction chemotherapy.
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Rate of hospital admission
During the 4-7 days of outpatient chemotherapy
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
United States: Federal Government
|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium||Seattle, Washington 98109|